Alcon (SWX:ALC) After The RxSight Deal Is The Growth Story Already Priced In

Alcon (SWX:ALC) is back in focus after announcing a non-exclusive collaboration with RxSight to co-develop adjustable presbyopia-correcting intraocular lenses. These lenses can be fine tuned after cataract surgery.

See our latest analysis for Alcon.

At a share price of CHF56.94, Alcon has seen short term momentum pick up, with a 1 month share price return of 8.42% and 7 day gain of 5.37%. However, the 1 year total shareholder return is down 17.89%, pointing to ongoing investor caution even as this RxSight collaboration brings the stock back into focus.

If this kind of medical technology story interests you, it could be a good time to broaden your watchlist by checking out 128 healthcare AI stocks

Alcon’s recent bounce highlights a simple tension: is this move mainly a catch-up to the company’s underlying progress in eye care, or is it mostly a sentiment swing that the valuation still needs to justify next?

Most Popular Narrative: 25.7% Undervalued

Alcon's most followed valuation narrative pins fair value at CHF76.62, comfortably above the last close at CHF56.94, which puts a spotlight on the growth and margin story analysts are using to bridge that gap.

Accelerated new product launches, including Unity VCS (next gen surgical platform), PanOptix Pro (premium IOL), Tryptyr (first in class dry eye Rx), Precision7 (novel contact lens), and recent pipeline accretive M&A (STAAR, LumiThera, Voyager), provide significant near and medium term opportunities for share gain, mix improvement, and new market entry. These factors underpin potential upside to both revenue and net margins as these innovations scale.

Read the complete narrative.

Want to see how this Alcon story turns higher procedure volumes, richer product mix and fatter margins into that higher fair value? The entire case rests on a carefully stepped path of revenue growth, rising profitability and a future earnings multiple that assumes investors keep paying up for this profile. Curious which specific growth and margin assumptions have to land for that CHF76.62 figure to hold up?

Result: Fair Value of CHF76.62 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Alcon story could be knocked off course if competitive pressure in intraocular lenses persists, or if recent acquisitions run into heavier regulatory and integration setbacks.

Find out about the key risks to this Alcon narrative.

Another View: What Alcon’s P/E Says

Our fair value work suggests Alcon looks attractive at CHF56.94, yet the P/E of 42x paints a tougher picture. That is richer than both the peer average of 26.7x and a fair ratio of 37.4x, which points to valuation risk if sentiment or growth expectations cool.

For readers who prefer to anchor on earnings multiples rather than cash flow models, the gap between a 42x P/E and both peers and the fair ratio is a reminder to stress test how much growth and margin expansion you are comfortable underwriting.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Taking all this into account, does the Alcon story feel more promising or more precarious to you right now? Review the latest figures promptly and weigh both sides of the debate by checking the 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Alcon?

If Alcon has sharpened your focus on healthcare, do not stop here. Broaden your opportunity set with other stocks that might suit your style and risk tolerance.

Use the Simply Wall Street Screener now to uncover fresh ideas that fit your goals and avoid leaving potential opportunities on the table.

• Target potential mispricings by scanning through companies flagged as 219 high quality undervalued stocks that may warrant a closer look on your watchlist.
• Prioritise resilience by reviewing companies in the 292 resilient stocks with low risk scores that may align with a steadier approach to capital preservation.
• Hunt for overlooked potential by checking the screener containing 506 high quality undiscovered gems that might not yet be widely followed by the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com